<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959425</url>
  </required_header>
  <id_info>
    <org_study_id>OAT-149</org_study_id>
    <nct_id>NCT01959425</nct_id>
  </id_info>
  <brief_title>Oral Anticoagulation Therapy Pilot Study</brief_title>
  <acronym>OAT</acronym>
  <official_title>Safety of Oral Anticoagulation Therapy Withdrawal After Successful Cardiac Ablation in Patients With Atrial Fibrillation and Associated High Risk Factors for Embolic Events (OAT Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the safety of discontinuing oral anticoagulation
      therapy in high risk patients who have had a successful cardiac ablation and remain AF
      recurrence free for 3 months post ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing successful cardiac ablation for atrial fibrillation who remain AF
      recurrence-free 3 months after successful ablation and continue to meet the
      inclusion/exclusion criteria will be screened for enrollment in the trial. After fulfilling
      all of the inclusion/exclusion criteria, patients who consent to participate in the study and
      remain AF recurrence-free will be randomized to one of two study arms: (1) OAT Withdrawal
      (Test) Group or (2) OAT (Control) Group and participate in the Evaluation Period (12 months).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2013</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of any major thromboembolic event</measure>
    <time_frame>12 months</time_frame>
    <description>Composite endpoint represented by the occurrence of any major thromboembolic event (stroke [i.e., ischemic, hemorrhagic or cryptogenic] that is an acute onset of a focal neurologic deficit of presumed vascular origin lasting for ≥24 hours or resulting in death) or major hemorrhagic complication (major bleeding) during the 12-month Evaluation Period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Minor bleeds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Hospitalization with any thromboembolic or major hemorrhagic event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of Life Questionnaire (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrence of atrial fibrillation- Subject with recurrence of atrial fibrillation will be immediately exited from the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat ablation</measure>
    <time_frame>12 months</time_frame>
    <description>Repeat ablation for atrial fibrillation- Subjects requiring a repeat ablation for AFib will be immediately exited from the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Off OAT Group (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Discontinuation of OAT Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>On OAT Group (Control)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Continuation of OAT Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Off OAT Group (Test)</intervention_name>
    <description>Discontinuation of OAT Therapy</description>
    <arm_group_label>Off OAT Group (Test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>On OAT Group (Control)</intervention_name>
    <description>Continuation of OAT Therapy</description>
    <arm_group_label>On OAT Group (Control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Successful cardiac ablation for AF

          2. Documented freedom from AF recurrence (symptomatic or asymptomatic arrhythmic
             recurrences lasting longer than 30 seconds) 3 months after successful cardiac ablation
             (AF recurrence during 3-month blanking period is excluded).

          3. Patient must have been on a commercially approved anticoagulation therapy for at least
             two (2) months prior to randomization in the OAT Study.

          4. CHADS2 score ≥ 2 or CHA2DS2-VASc score (≥3)

          5. Left ventricular ejection fraction &gt; 25%

          6. LA size &lt; 65

          7. High risk for thromboembolic events (i.e., CHADS2 score ≥ 2 or CHA2DS2-VASc score ≥ 3)
             and require OAT before undergoing cardiac ablation

          8. Able and willing to comply with all pre- and follow-up testing and requirements

          9. Signed informed consent form

         10. Age 18 years or older

        Exclusion Criteria:

          1. OAT required for reasons not related to AF (i.e., prosthetic valve, PV stenosis,
             previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard
             echo performed at 3-months follow-up).

          2. Any cardiac surgery within the past 60 days (2 months) or valvular cardiac surgical
             procedure at any time (i.e., ventriculotomy, atriotomy, and valve repair or
             replacement and presence of a prosthetic valve)

          3. Previous myocardial infarction (MI) or a percutaneous coronary intervention PCI within
             the past 3 months

          4. Awaiting cardiac transplantation or other cardiac surgery within the next 365 days (12
             months)

          5. Documented left atrial thrombus

          6. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or
             COPD) or any other disease or malfunction of the lungs or respiratory system that
             produces chronic symptoms

          7. Significant medical problem that in the opinion of the investigator would preclude
             enrollment in this study

          8. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)

          9. Acute illness or active systemic infection or sepsis

         10. Unstable angina

         11. Contraindication to anticoagulation (i.e., heparin, warfarin or another commercially
             available anticoagulation medication)

         12. History of blood clotting or bleeding abnormalities

         13. Life expectancy less than 360 days (12 months)

         14. Uncontrolled Heart Failure or NYHA Class III or IV heart failure

         15. Enrollment in a clinical study evaluating another device or drug, within the past 6
             months

         16. Unable or unwilling to comply with protocol requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Natale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Cardiac Arrhythmia Research Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Raviele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dell'Angelo Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Riley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Heinz Kuck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanseatisches Herzzentrum, Asklepios Klinik</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Haissaguerre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Cardiologigue du Haut-Leveque</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Jais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Cardiologigue du Haut-Leveque</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sakis Themistoclakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dell'Angelo Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Hendricks</last_name>
    <phone>(909) 839-8447</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janel Noche</last_name>
    <phone>(909) 839-7720</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kansas Hospitals</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Gunter</last_name>
      <phone>913-588-5969</phone>
      <email>mgunter@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Dhanunjaya Lakkireddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pete Leo</last_name>
      <phone>216-778-2714</phone>
      <email>pleo@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Ohad Ziv, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosanne Clayton</last_name>
      <phone>215-615-5226</phone>
      <email>Rosanne.Clayton@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Riley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Cardinal, RN</last_name>
      <phone>512-458-9410</phone>
      <email>dscardinal@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andrea Natale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Centre Hospitalier de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <state>Pessac</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Brunello</last_name>
      <phone>+33 5 57 62 30 91</phone>
      <email>isabelle.brunello@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Jais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sakine Struck</last_name>
      <phone>+49 40 1818 85 3303</phone>
      <email>s.struck@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Karl-Heinz Kuck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Rossillo, MD</last_name>
      <email>antoniorossillo@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Sakis Themistoclakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticoagulation</keyword>
  <keyword>Oral</keyword>
  <keyword>Paroxysmal atrial fibrillation</keyword>
  <keyword>Patients post successful cardiac ablation</keyword>
  <keyword>Symptomatic high-burden paroxysmal AF</keyword>
  <keyword>3 months post procedure</keyword>
  <keyword>Remain free from AF recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

